Jan 04,2023

Know Labs wins new glucose monitoring patent

Know Labs announced today that it received a new patent equating its diagnostic technology to the current glucose monitoring standard. Seattle-based Know Labs develops the Bio-RFID technology. It uses spectroscopy to direct electromagnetic energy through a substance or material to capture a unique molecular signature. It integrate into wearable, mobile or bench-top form factors. The first application of the technology comes in the form of a non-invasive glucose monitor.

PRODUCT

#cgm

View Analyst & Ambassador Comments
Go to original news
Jan 13,2023

How Dexcom aims to extend its mission beyond diabetes

CEO Kevin Sayer explains how, following the launch of the next-generation Dexcom G7, the company is looking toward the future. Dexcom ended 2022 strong, receiving FDA clearance for its next-generation G7 continuous glucose monitor (CGM). With a U.S. launch imminent, the company could keep its efforts centered on the diabetes space. Instead, the company could keep its efforts centered on the diabetes space. Instead, the company plans to broaden its focus even wider.

#cgm

View Analyst & Ambassador Comments
Go to original news
Jan 17,2023 TOP STORY

Dexcom G6 Real-Time CGM System Now Available to All Clients With Type 1 Diabetes Covered Under the Non-Insured Health Benefits Program

Dexcom, Inc. is pleased to announce that coverage for Dexcom G6 rtCGM System on the Non-Insured Health Benefits (NIHB) Program has been expanded to include all clients living with type 1 diabetes. This announcement expands upon coverage already in place for clients aged 2 to 19 on intensive insulin therapy, giving even more First Nations and Inuit people access to this standard of care, potentially helping them to have more control over a life-long chronic illness.

PRODUCT

#cgm

View Analyst & Ambassador Comments
Go to original news
Jan 20,2023

The quest for a truly artificial pancreas

Recently, continuous glucose monitors and programmable insulin patch pumps have started to be called an ‘artificial pancreas’ system, as they are able monitor and manage glucose levels with minimal action from the patient. This artificial pancreas is generally all that is required for patients with type 2 diabetes to successfully manage their condition and allows for more flexibility in their days and activities. However, this system does not address glucagon deficiency, which affects type 1 diabetes patients but not type 2 diabetes patients due to differences in pathology. Insulin lowers blood glucose while glucagon raises it. Dual-hormone pumps are intended to supply both insulin and glucagon. Beta Bionics is currently seeking approval from the FDA for the iLet Bionic Pancreas, both as a stand-alone insulin pump and later as a dual-hormone pump.

PRODUCT

#insulin pump

#cgm

View Analyst & Ambassador Comments
Go to original news
Jan 24,2023

Nemaura Medical Reports Initial Patient Data from UK NHS Miboko Study that Demonstrates Weight Loss in 100% of Participants

Nemaura Medical announces initial results from patient studies of its metabolic health program Miboko with the National Health Service (NHS) in the United Kingdom. The initial pilot program recruited 30 individuals that were classified as obese according to their BMI. The first cohort of 10 patients have been enrolled in the program for over 12 weeks. Results from this cohort indicate that these individuals achieved an average weight loss of 3.7 pounds and an average BMI improvement of 0.6 after 10 weeks, with 100% of participants achieving some weight improvement.

CLINICAL STUDY

#cgm

#coaching

#mobile app

View Analyst & Ambassador Comments
Go to original news
Jan 25,2023

The year ahead in diabetes care: what to expect in 2023

After a banner year for diabetes technology in 2022, there’s still plenty to look forward to in 2023. Throughout 2022, we saw a wide range of advancements in diabetes technology. We saw launches for next-generation technologies, exciting clinical trial results, rumored spinouts and acquisitions and more. As we embark on a new year in 2023, there’s still plenty to look forward to in the diabetes space. Here are a few things worth keeping an eye on.

#cgm

#insulin pump

View Analyst & Ambassador Comments
Go to original news
Jan 27,2023

Nemaura Medical garners U.S.-based purchase order for glucose sensors

Nemaura Medical announced that it received a purchase order for 5,000 proBEAT glucose sensor subscriptions. HealthFleet, a U.S.-based telehealth provider, made the purchase order. It consists of 75,000 proBEAT glucose sensors over an initial five-month period. Nemaura values the deal at $500,000 in revenue, while HealthFleet possesses the option to increase volumes based on customer response.

PRODUCT

#cgm

View Analyst & Ambassador Comments
Go to original news
Dec 01,2022

Dexcom G6 CGMs win reimbursement coverage in Japan

Terumo announced today that the Japanese medical insurance system expanded reimbursement coverage for the Dexcom G6 CGM. Japan’s medical insurance system introduced a new category titled “C150.” It makes a wider range of people with diabetes eligible to receive reimbursement for the G6 continuous glucose monitor (CGM) in Japan. Terumo markets the G6 in Japan, according to a news release.

PRODUCT

#cgm

View Analyst & Ambassador Comments
Go to original news
Dec 05,2022

Scientists Develop 12-Hour Method to Predict Diabetes Onset in Patients Using AI

Scientists at Klick Applied Sciences have discovered a way to transform a continuous glucose monitor (CGM) into a powerful diabetes screening and prevention tool using artificial intelligence. In findings presented Friday at the NeurIPS conference in New Orleans, Klick scientists revealed how they used machine learning and just 12 hours of data from CGMs to determine whether a patient was prediabetic or diabetic. Jeon said they discovered their 12-hour model showed similar high accuracy to results from the longer intervals, correctly identifying two-thirds of patients with prediabetes, while also showing high accuracy in identifying healthy patients and those with Type 2 diabetes.

CLINICAL STUDY

#cgm

View Analyst & Ambassador Comments
Go to original news
Dec 06,2022

Efficacy of a Connected Insulin Pen Cap in People With Noncontrolled Type 1 Diabetes: A Multicenter Randomized Clinical Trial

The objective of the study is to assess the efficacy of the insulin pen cap Insulclock on improving glycemic control, treatment adherence, and user satisfaction in people with type 1 diabetes.

CLINICAL STUDY

#insulin pen

#cgm

View Analyst & Ambassador Comments
Go to original news
Subscribe to CGM